Wednesday, May 25, 2022
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina



Brazil authorized India´s Covaxin vaccine clinical trials

Brazil authorized India´s Covaxin vaccine clinical trials

Brasilia, May 14 (Prensa Latina) The National Health Surveillance Agency (ANVISA) on Thursday authorized clinical trials of Covaxin, an anti-Covid-19 vaccine candidate developed by Indian Pharmaceutical Company Bharat Biotech.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

ANVISA forecasts that as many as 4,500 volunteers will participate in the tests: 3,000 in Sao Paulo and 500 in Rio de Janeiro, Bahia and Mato Grosso.

At the end of March, ANVISA denied to import 20 million Covaxin doses into national territory.

In April, Bharat Biotech reported it expanded its manufacturing capacity at various facilities to produce 700 million doses per year.

The Indian pharmaceutical company said it can expand in a short time thanks to the brand-new BSL-3 facilities, the first of its kind for Covaxin vaccine manufacturing in India.

To further increase doses, Bharat Biotech partnered with Indian Immunologicals to manufacture Covaxin´s pharmacological substance.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.